Health · 1 sources covering this

STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts

A little-noticed government policy shift caused a seven-year delay in choosing a costly medicine for Medicare price negotiations, an advocacy group says.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
A little-noticed government policy shift caused a seven-year delay in choosing a costly medicine for Medicare price negotiations, an advocacy group says.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/15802d05169e1a47e2b5c904521176f91c4db0b1"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts"></iframe>

STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts

How 1 sources are covering this

STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts

More from Health

STAT+: FDA approves Replimune melanoma drug previously rejected twice

A new flu vaccine geared to older people is coming soon

STAT+: Study reveals new role for tau, a top target for Alzheimer’s drug development

STAT+: Two FDA approvals — a new drug and a new vaccine

Reader

Trust & legal

Across the network